Researchers investigated immune-related adverse effects and characteristics that may predict their incidence in patients receiving ICIs for gastrointestinal cancers.

Researchers aim to validate the AI tool SCORPIO in prospective studies and eventually seek FDA clearance to sell it as a commercial tool in the US.

New research highlights a link between immune checkpoint inhibitors (ICIs) and an increased risk of autoimmune diseases, including rheumatoid arthritis, emphasizing the need for vigilance among ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

The following is a summary of “Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Ocular inflammation and vision-threatening adverse events to cancer therapies can be mitigated once researchers understand their mechanisms.

As immunotherapy has revolutionized cancer treatment, a wide array of immune-related adverse events (irAEs) has emerged. Among these irAEs, those involving ...

The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment by harnessing the immune system to target and eliminate cancer cells.

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.